factually
Index/Topics/Caplyta Approval and Efficacy

Caplyta Approval and Efficacy

The FDA approval and efficacy of Caplyta (lumateperone) for schizophrenia, bipolar depression, and major depressive disorder in adults.

Fact-Checks

1 result
Feb 4, 2026

Caplyta

(lumateperone) is an atypical antipsychotic approved by the initially in December 2019 for schizophrenia and later for bipolar depression; it is also indicated as adjunctive therapy for major depressi...